Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ethris Announces Research Based Alliance on SNIM® Modified RNA with Shire

Published: Monday, January 07, 2013
Last Updated: Monday, January 07, 2013
Bookmark and Share
SNIM®-RNA molecules are ideally suited for use in protein replacement therapies to treat monogenic genetic diseases.

Ethris GmbH and Shire have announced the initiation of a research based alliance focused on the development and commercialization of novel RNA-based therapeutics.

Many devastating human diseases are the result of an inability of the body’s cells to make specific proteins that have an essential function for the whole body.

The replacement of proteins with normally functioning ones provides a potential approach to treat multiple devastating diseases.

Ribonucleic acids (RNAs) that encode for such proteins have been the focus of much biopharmaceutical research and development, however, RNA’s inherent instability and immunogenicity has proven to be a significant hurdle in the past.

Based in Munich, Germany, Ethris and its co-founders - Dr. Carsten Rudolph and Prof. Christian Plank, have developed a novel RNA modification technology that creates Stable and Non-Immunogenic Messenger RNA (SNIM®-RNA) molecules that are ideally suited for use in protein replacement therapies to treat monogenic genetic diseases.

“We are delighted to extend our existing collaboration with Shire that may bring novel therapeutics to patients suffering diseases with significant unmet medical need. We aim to provide significant numbers of patients with new therapeutic alternatives that may provide a lasting solution to their disease,” stated Dr. Carsten Rudolph, CEO and co-founder of ethris.

“As a leader in the treatment of rare diseases, we are pleased to be working with ethris to develop SNIM®-RNA based therapies, with the objective of developing new treatment options to patients suffering from these rare disorders” said Dr. Philip J. Vickers, Global Head of Research and Development, Shire Human Genetic Therapies.

“With Shire we have a partnership based on a shared appreciation of the importance of our SNIM® technology. Under this partnership, we are aiming to develop an RNA modification and delivery technology that efficiently results in protein replacement in relevant cellular populations, providing hope to patients suffering from genetic diseases which have devastating clinical outcomes” commented Prof. Christian Plank CSO and co-founder of ethris.

The financial details of the alliance have not been disclosed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Biomarkers That Could Help Give Cancer Patients Better Survival Estimates Discovered
UCLA research may also help scientists suppress dangerous genetic sequences.
Body’s Own Gene Editing System Generates Leukemia Stem Cells
Inhibiting the editing enzyme may provide a new therapeutic approach for blood cancers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!